Search results
In clinical trials for mRNA COVID-19 bivalent booster doses, rates of local or systemic adverse events were similar or less frequent after a bivalent booster as a 4th dose than after the 2 nd dose of primary series vaccination or monovalent booster as a 3 rd dose.
The Pfizer bivalent vaccine can be used as an alternative vaccine to any of the available mRNA COVID-19 vaccines (Pfizer original vaccine, Moderna bivalent vaccine or Moderna original vaccine) for any booster dose in people aged 18 years or older who are currently recommended to receive a COVID-19 booster.
Jan 19, 2023 · Discussion. In this online survey aimed at understanding reasons for low bivalent COVID-19 booster vaccination coverage, the most common reasons for not receiving a bivalent booster dose were lack of awareness of eligibility (23.2%) or availability (19.3%) and perceived existing protection against infection (18.9%), although top reasons differed across age groups.
Apr 13, 2023 · Participants who received a bivalent mRNA booster vaccine dose had lower rates of hospitalisation due to COVID-19 than participants who did not receive a bivalent booster vaccination, for up to 120 days after vaccination. These findings highlight the importance of bivalent mRNA booster vaccination in populations at high risk of severe COVID-19. Further studies with longer observation times are ...
Nov 15, 2022 · ¶ A monovalent Novavax booster dose (rather than a bivalent mRNA booster dose) may be used in limited situations in adults aged ≥18 years who completed any FDA-approved or FDA-authorized monovalent primary series, have not received any primary booster doses, and are unable to receive an mRNA vaccine (i.e., mRNA vaccine is contraindicated or ...
Single-dose vials are intended to be prioritized for increasing access to the bivalent COVID-19 booster—e.g., making it available in more locations, increasing access through mobile clinics, etc. Multi-dose vials of the Pfizer Bivalent Booster (Ages 12+) remain available for ordering. Single-dose vials are a one-for-one match for potential ...
On Wednesday, the FDA authorized the Novavax COVID-19 Vaccine, Adjuvanted for use as a first booster dose to individuals 18 years of age and older for whom an FDA-authorized mRNA bivalent COVID-19 ...
